Hong Ge, MD

The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital

Disclosures:

  • Employment: none
  • Compensation: none
  • Ownership: none
  • Leadership: none

Presentations

Sep 27

2069 - Four-year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Chemoradiotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Study
03:00pm - 04:00pm ET
Sep 27

2070 - Survival Outcomes of Adjuvant Immunotherapy after Neoadjuvant Chemoimmunotherapy Followed by Esophagectomy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
03:00pm - 04:00pm ET
Sep 29

274 - Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial
12:40pm - 12:50pm ET
Sep 29

3474 - Stereotactic Body Radiotherapy Combined with PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Single-Arm Trial
03:45pm - 05:00pm ET